Cancer Treatments Are Driving Biopharmaceutical M&A

It’s been a busy year for mergers and acquisitions in the Biotechnology and Pharmaceutical industries. Combined spending on M&A is close to $268 billion mid-way through December, with 229 transactions reported. Although the number of deals is 34% lower than 2018’s combined total of 345, spending skyrocketed 62%, from just $165 billion in all of […]

August Deal Flow Ebbs, as It Follows the Annual Cycle

Enough about slowdowns and recession. August is typically a roller-coaster month in the equity markets and August 2019 didn’t disappoint in that regard. The bond markets’ inverted yield curve persisted into September and that’s never a good sign. We’re moving on. Preliminary data show August’s deal volume wasn’t so bad, considering how most of 2019 […]

big pharma
big pharma

Celgene Sells Otezla to Advance its Sale to Bristol-Myers Squibb

Amgen (NASDAQ: AMGN) has agreed to take Otezla (apremilast) off of Celgene Corporation‘s (NASDAQ: CELG) hands. The Federal Trade Commission ruled the drug had to be divested due to concerns over competition with Bristol-Myers Squibb‘s (NYSE: BMY) pipeline. Bristol-Myers announced it was buying Celgene last January for $74 billion. In this deal, Amgen gains the worldwide […]

Healthcare Dollar Volume Exploded in January

Dollar volume for healthcare deals announced in January was ridiculous, topping $90 billion. We don’t see figures like that in most quarters. The outsized total results from a single deal, of course. Bristol-Myers Squibb’s (NYSE: BMY) $74 billion acquisition of Celgene Corp. (NASDAQ: CELG) made up 81% of the month’s total. Suffice it to say […]


Bristol-Myers Squibb Surprises with Celgene Deal

Twas a week before the J.P. Morgan Healthcare Summit, and everything was quiet on the life sciences front. December deal-making hit a wall, with pharmaceutical deals falling 50% compared with last December. Then came Bristol-Myers Squibb‘s (NYSE: BMY) announcement it was acquiring Celgene Corporation (NASDAQ: CELG) for approximately $90 billion. This isn’t the biggest pharma […]

Amazon Scoops Up PillPack for $1 Billion

Amazon (NASDAQ: AMZN) finally took the plunge into the pharmaceutical market with its approximately $1 billion acquisition of five-year-old PillPack, an online pharmacy startup based in Manchester, New Hampshire. Financial terms weren’t disclosed in the deal’s announcement, but on June 28, the day of the announcement, The Wall Street Journal quoted sources on the price. In April […]

Gilead Buys Kite Pharma to Diversify Portfolio

Gilead Sciences, Inc. (NASDAQ: GILD) finally found a target worth pursuing. The pharmaceutical company, perhaps best known for its high-priced hepatitis-C drugs, Harvoni and Solvadi, placed its bets on Kite Pharma, Inc. (NASDAQ: KITE), hoping to cash in on the biotech’s promising technology for fighting cancer.

Biotech Boomed Even Before Trump’s Election

Now that Donald Trump has transitioned from presidential candidate to president-elect, his pro-business views have cheered many deal makers. His “repeal and replace” pronouncements regarding the Affordable Care Act have chilled some areas of the healthcare market, but others are thriving.